ReviewACS omega2026
Stimuli-Responsive Polyethylenimine Derivatives as Carriers for siRNA Delivery: Current Solutions and Future Perspectives.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA therapeutics, particularly small interfering RNA, hold great promise for precise gene silencing but still face major challenges related to instability, inefficient delivery, and off-target effects. Polyethylenimine (PEI), a versatile polycation, exhibits strong nucleic acid binding capacity, efficient endosomal escape, and high structural adaptability, making it one of the most promising nonviral delivery platforms. This review summarizes recent advances in stimuli-responsive PEI-based systems, classified according to endogenous triggers such as pH gradients, reactive oxygen species, enzymatic activity, and ATP, as well as exogenous stimuli such as light, temperature, and magnetic fields. Reported strategies include chemical modification, polymer grafting, hybridization with inorganic nanomaterials, and fluorination to enhance specificity, transfection efficiency, and biocompatibility while reducing cytotoxicity. Dual- and multistimuli-responsive designs further enable spatiotemporally controlled release, thereby improving therapeutic efficacy both
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.